Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation

Diagnosis and treatment of thyroid cancer (TC) are undergoing radical changes, shifting from traditional tissue studies to liquid biopsies (LB). LB technologies provide effective, non-invasive solutions to these challenges. This paper reviews recent advances in the analysis of three important biomarker systems: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes. Technically, microfluidics and bioaffinity-based physical capture strategies have significantly improved the efficiency with which CTCs can be separated and analysed at an individual cell level. Ultra-sensitive digital polymerase chain reaction (dPCR) and targeted sequencing enable accurate characterization of rare mutations and methylation alterations in ctDNA. Additionally, innovations in ultracentrifugation and new microfluidic chips have improved the efficiency with which exosomes and the information molecules they contain (e.g., miRNA and lncRNA) are extracted and detected. These abundant liquid biomarkers demonstrate significant value in clinical translation. CTCs provide a unique opportunity to study the mechanisms of metastasis and tumor heterogeneity, while ctDNA plays a central role in preoperative risk classification, monitoring minimal residual disease and tracking the dynamics of drug-resistant mutations. Exosomes, as stable carriers of nucleic acids, have significant potential for early diagnosis and assessment of treatment efficacy. Nevertheless, this field still faces significant challenges, including a lack of technical standardization and integration of different biomarker results, insufficient sensitivity in patients with low tumor burden and a lack of broad preclinical validation. In the future, joint analysis of multigenomic biomarkers and deep integration of the latest technologies, such as microfluidics and artificial intelligence, promise to create a more comprehensive ecosystem for precise TC diagnosis and treatment.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-03-31
DOI
https://doi.org/10.3389/fendo.2026.1757547
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation

Ye Gao, Xiaolin Hou, Hongxia Fu, Yufei Wei et al.
Frontiers in Endocrinology
Thyroid Cancer Diagnosis and Treatment
article

Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation

Ye Gao, Xiaolin Hou, Hongxia Fu, Yufei Wei, Huiling Li, Lei Li, Qiyue Duan, Shujuan Wang
article en

Abstract

Diagnosis and treatment of thyroid cancer (TC) are undergoing radical changes, shifting from traditional tissue studies to liquid biopsies (LB). LB technologies provide effective, non-invasive solutions to these challenges. This paper reviews recent advances in the analysis of three important biomarker systems: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes. Technically, microfluidics and bioaffinity-based physical capture strategies have significantly improved the efficiency with which CTCs can be separated and analysed at an individual cell level. Ultra-sensitive digital polymerase chain reaction (dPCR) and targeted sequencing enable accurate characterization of rare mutations and methylation alterations in ctDNA. Additionally, innovations in ultracentrifugation and new microfluidic chips have improved the efficiency with which exosomes and the information molecules they contain (e.g., miRNA and lncRNA) are extracted and detected. These abundant liquid biomarkers demonstrate significant value in clinical translation. CTCs provide a unique opportunity to study the mechanisms of metastasis and tumor heterogeneity, while ctDNA plays a central role in preoperative risk classification, monitoring minimal residual disease and tracking the dynamics of drug-resistant mutations. Exosomes, as stable carriers of nucleic acids, have significant potential for early diagnosis and assessment of treatment efficacy. Nevertheless, this field still faces significant challenges, including a lack of technical standardization and integration of different biomarker results, insufficient sensitivity in patients with low tumor burden and a lack of broad preclinical validation. In the future, joint analysis of multigenomic biomarkers and deep integration of the latest technologies, such as microfluidics and artificial intelligence, promise to create a more comprehensive ecosystem for precise TC diagnosis and treatment.

Frontiers in EndocrinologyVol. 17
Shanxi Medical University (CN), First Hospital of Shanxi Medical University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Shanxi Province
Openalex Percentile: Top 37%
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.